Showing results (1-10 of 327) with videos related to
Sort By:
Pageof 33
Expert Opinion on Pharmacotherapy|June 27, 2013
Dapagliflozin for the treatment of type 2 diabetesMuhammad A Abdul-Ghani, Ralph A DeFronzoThe Journal of Clinical Endocrinology and Metabolism|June 24, 2011
Preservation of β-cell function: the key to diabetes preventionRalph A DeFronzo, Muhammad A Abdul-GhaniJournal of Biomedicine & Biotechnology|May 7, 2010
Pathogenesis of insulin resistance in skeletal muscleMuhammad A Abdul-Ghani, Ralph A DeFronzoEndocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 11, 2008
Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitusMuhammad A Abdul-Ghani, Ralph A DeFronzoCurrent Diabetes Reports|July 16, 2008
Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitusMuhammad A Abdul-Ghani, Ralph A DeFronzoCurrent Diabetes Reports|June 4, 2009
Pathophysiology of prediabetesMuhammad A Abdul-Ghani, Ralph A DeFronzoEndocrine Reviews|May 25, 2011
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetesMuhammad A Abdul-Ghani, Luke Norton, Ralph A DefronzoWorld Journal of Diabetes|October 15, 2015
Treatment of prediabetesMustafa Kanat, Ralph A DeFronzo, Muhammad A Abdul-GhaniAmerican Journal of Physiology. Renal Physiology|September 11, 2015
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusMuhammad A Abdul-Ghani, Luke Norton, Ralph A DeFronzoDiabetes|September 26, 2013
Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humansMuhammad A Abdul-Ghani, Ralph A DeFronzo, Luke NortonPageof 33